Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link



Dow Jones Industrial Average



) is trading down 23.0 points (-0.1%) at 16,982 as of Wednesday, Oct 29, 2014, 12:36 p.m. ET. During this time, 132.1 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 323.8 million. The NYSE advances/declines ratio sits at 1,291 issues advancing vs. 1,724 declining with 155 unchanged.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

The Dow component leading the way higher looks to be



TheStreet Recommends


), which is sporting a 49-cent gain (+0.9%) bringing the stock to $56.34. Volume for Merck currently sits at 5.6 million shares traded vs. an average daily trading volume of 9.7 million shares.

Merck has a market cap of $162.84 billion and is part of the health care sector and drugs industry. Shares are up 11.6% year-to-date as of Tuesday's close. The stock's dividend yield sits at 3.1%.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide.

TheStreet Ratings rates Merck as a


. The company's strengths can be seen in multiple areas, such as its solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more